NASDAQ:SWAV Shockwave Medical (SWAV) Stock Price, News & Analysis → The AI stock to buy right now (From StockEarnings) (Ad) Free SWAV Stock Alerts $330.94 +0.94 (+0.28%) (As of 02:42 PM ET) Add Compare Share Share Today's Range$330.00▼$331.0050-Day Range$251.71▼$330.1952-Week Range$157.00▼$331.58Volume425,890 shsAverage Volume935,584 shsMarket Capitalization$12.41 billionP/E Ratio85.51Dividend YieldN/APrice Target$309.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Shockwave Medical alerts: Email Address Shockwave Medical MarketRank™ Stock AnalysisAnalyst RatingHold2.09 Rating ScoreUpside/Downside6.3% Downside$309.11 Price TargetShort InterestHealthy3.92% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.99Based on 6 Articles This WeekInsider TradingSelling Shares$22.08 M Sold Last QuarterProj. Earnings Growth26.11%From $4.94 to $6.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.66 out of 5 starsMedical Sector70th out of 909 stocksSurgical & Medical Instruments Industry12th out of 96 stocks 2.0 Analyst's Opinion Consensus RatingShockwave Medical has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 1 buy rating, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageShockwave Medical has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.92% of the outstanding shares of Shockwave Medical have been sold short.Short Interest Ratio / Days to CoverShockwave Medical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shockwave Medical has recently decreased by 27.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldShockwave Medical does not currently pay a dividend.Dividend GrowthShockwave Medical does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreShockwave Medical has received a 72.86% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic and treatment machines" and "Medical devices engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Shockwave Medical is -0.55. Previous Next 2.2 News and Social Media Coverage News SentimentShockwave Medical has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Shockwave Medical this week, compared to 7 articles on an average week.Search InterestOnly 12 people have searched for SWAV on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Shockwave Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Shockwave Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,081,356.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Shockwave Medical is held by insiders.Percentage Held by Institutions95.35% of the stock of Shockwave Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Shockwave Medical are expected to grow by 26.11% in the coming year, from $4.94 to $6.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shockwave Medical is 85.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Shockwave Medical is 85.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 193.58.Price to Earnings Growth RatioShockwave Medical has a PEG Ratio of 2.45. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioShockwave Medical has a P/B Ratio of 18.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Shockwave Medical Stock (NASDAQ:SWAV)Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.Read More SWAV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWAV Stock News HeadlinesApril 13, 2024 | marketbeat.comMarketBeat Week in Review – 4/8 - 4/12 (SWAV)The latest inflation readings moved stocks lower as investors reconsidered what higher-for-longer interest rates mean for corporate earnings and stock valuationApril 8, 2024 | marketbeat.comWill the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?On April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, which is a 4.75% premium compared to Shockwave's closing price on April 4, 2024.May 3, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 8, 2024 | marketbeat.comWill the Shockwave Medical Deal Be the Jolt JNJ Stock Needs? (SWAV)Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrendApril 5, 2024 | marketbeat.comNewmont, Shockwave Medical rise; John Bean fall, Friday, 4/4/2024Stocks that are trading heavily or have substantial price changes on Friday: Newmont, Shockwave Medical rise; John Bean fallApril 30, 2024 | americanbankingnews.comContrasting Shockwave Medical (NASDAQ:SWAV) and Pro-Dex (NASDAQ:PDEX)April 27, 2024 | americanbankingnews.comShockwave Medical, Inc. (NASDAQ:SWAV) Given Consensus Rating of "Hold" by BrokeragesApril 26, 2024 | benzinga.comMonthly Depth Report: The Blind Leading The ConfusedMay 3, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 24, 2024 | finance.yahoo.comShockwave Medical (SWAV) Rose on an Acquisition News and Solid Financial ResultApril 18, 2024 | msn.comShockwave Medical (SWAV) Price Target Increased by 17.23% to 322.46April 16, 2024 | finance.yahoo.comJ&J CFO on Q1 Earnings, Forecast and Product PipelineApril 12, 2024 | finance.yahoo.comPharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory NewsApril 12, 2024 | finance.yahoo.comShockwave Medical (SWAV) Rose on Strong Financial ResultsApril 11, 2024 | benzinga.com5 Things To Know In Investing This Week - The Shockwave Takeover IssueApril 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, INRDApril 9, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Shockwave Medical, Inc. - SWAVApril 8, 2024 | businesswire.comSHOCKWAVE MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Shockwave Medical, Inc. - SWAVApril 8, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Shockwave Medical (SWAV)April 8, 2024 | finance.yahoo.comShockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ StudyApril 8, 2024 | globenewswire.comShockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World' StudyApril 6, 2024 | msn.comJ&J Buys Shockwave Medical for $13.1B, Boosting Its Cardiovascular Treatment PortfolioApril 5, 2024 | prnewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.April 5, 2024 | msn.comJohnson & Johnson Buys Shockwave Medical For $12.5 BillionApril 5, 2024 | investopedia.comJ&J Acquires Shockwave Medical to Boost Its Cardiovascular Treatment PortfolioApril 5, 2024 | proactiveinvestors.comJohnson & Johnson to acquire medical device company Shockwave Medical for $13.1BApril 5, 2024 | wsj.comJohnson & Johnson to Buy Shockwave Medical in $13.1 Billion DealSee More Headlines Receive SWAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shockwave Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today5/03/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:SWAV CUSIPN/A CIK1642545 Webwww.shockwavemedical.com Phone(877) 775-4846FaxN/AEmployees1,468Year FoundedN/APrice Target and Rating Average Stock Price Target$309.11 High Stock Price Target$368.00 Low Stock Price Target$210.00 Potential Upside/Downside-6.3%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$3.87 Trailing P/E Ratio85.29 Forward P/E Ratio66.81 P/E Growth2.45Net Income$147.28 million Net Margins20.17% Pretax Margin23.87% Return on Equity23.97% Return on Assets12.78% Debt Debt-to-Equity Ratio1.09 Current Ratio11.76 Quick Ratio10.73 Sales & Book Value Annual Sales$730.23 million Price / Sales16.95 Cash Flow$4.32 per share Price / Cash Flow76.47 Book Value$18.12 per share Price / Book18.22Miscellaneous Outstanding Shares37,510,000Free Float36,233,000Market Cap$12.38 billion OptionableOptionable Beta0.88 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Douglas E. Godshall M.B.A. (Age 59)President, CEO & Director Comp: $1.57MMr. Daniel Hawkins (Age 57)Founder and Senior Advisor Mr. John M. Adams (Age 77)Co-Founder and Technical Advisor Ms. Renee M. Gaeta (Age 43)Chief Financial Officer Mr. Luis MoralesSenior Vice President of Global OperationsMs. Trinh Phung (Age 46)Chief Accounting Officer, Principal Accounting Officer & VP of Finance Ms. Debbie KasterVice President of Investor RelationsMr. Hajime Tada J.D.General Counsel & SecretaryMr. Robert FletcherSenior Vice President of Marketing & Market AccessMr. Dave CoxVice President of SalesMore ExecutivesKey CompetitorsInsuletNASDAQ:PODDSolventumNYSE:SOLVTeleflexNYSE:TFXPenumbraNYSE:PENInspire Medical SystemsNYSE:INSPView All CompetitorsInsiders & InstitutionsCentral Pacific Bank Trust DivisionBought 1,714 shares on 5/3/2024Ownership: 0.005%BI Asset Management Fondsmaeglerselskab A SBought 368 shares on 5/3/2024Ownership: 0.001%Nordea Investment Management ABSold 815 shares on 5/2/2024Ownership: 0.094%Mutual of America Capital Management LLCSold 1,225 shares on 5/2/2024Ownership: 0.072%Fidelis Capital Partners LLCBought 137 shares on 5/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SWAV Stock Analysis - Frequently Asked Questions Should I buy or sell Shockwave Medical stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last twelve months. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SWAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SWAV, but not buy additional shares or sell existing shares. View SWAV analyst ratings or view top-rated stocks. What is Shockwave Medical's stock price target for 2024? 11 analysts have issued 1 year price targets for Shockwave Medical's stock. Their SWAV share price targets range from $210.00 to $368.00. On average, they expect the company's share price to reach $309.11 in the next year. This suggests that the stock has a possible downside of 6.3%. View analysts price targets for SWAV or view top-rated stocks among Wall Street analysts. How have SWAV shares performed in 2024? Shockwave Medical's stock was trading at $190.56 at the beginning of 2024. Since then, SWAV shares have increased by 73.2% and is now trading at $330.06. View the best growth stocks for 2024 here. Are investors shorting Shockwave Medical? Shockwave Medical saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 1,470,000 shares, a decrease of 27.6% from the March 31st total of 2,030,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is presently 1.4 days. View Shockwave Medical's Short Interest. When is Shockwave Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SWAV earnings forecast. How were Shockwave Medical's earnings last quarter? Shockwave Medical, Inc. (NASDAQ:SWAV) posted its quarterly earnings results on Thursday, February, 15th. The company reported $1.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.24. The firm earned $202.98 million during the quarter, compared to analysts' expectations of $199.43 million. Shockwave Medical had a net margin of 20.17% and a trailing twelve-month return on equity of 23.97%. The company's revenue for the quarter was up 41.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.71 earnings per share. What ETFs hold Shockwave Medical's stock? ETFs with the largest weight of Shockwave Medical (NASDAQ:SWAV) stock in their portfolio include Invesco S&P MidCap 400 GARP ETF (GRPM), Neuberger Berman Disrupters ETF (NBDS), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Invesco S&P MidCap 400 GARP ETF (EWMC), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Motley Fool Mid-Cap Growth ETF (TMFM) and ProShares Merger ETF (MRGR). What guidance has Shockwave Medical issued on next quarter's earnings? Shockwave Medical issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $910.0 million-$930.0 million, compared to the consensus revenue estimate of $918.9 million. What is Doug Godshall's approval rating as Shockwave Medical's CEO? 8 employees have rated Shockwave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees. What other stocks do shareholders of Shockwave Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA). When did Shockwave Medical IPO? Shockwave Medical (SWAV) raised $75 million in an initial public offering (IPO) on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Shockwave Medical's major shareholders? Shockwave Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.38%), Baillie Gifford & Co. (0.61%), WCM Investment Management LLC (0.42%), Principal Financial Group Inc. (0.37%), Artemis Investment Management LLP (0.23%) and Jennison Associates LLC (0.17%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Frederic H Moll, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sara Toyloy and Trinh Phung. View institutional ownership trends. How do I buy shares of Shockwave Medical? Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SWAV) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shockwave Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
